![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1522780
¼¼°èÀÇ ÀÎÅ©·¹Æ¾ °ü·Ã ¾à¹° ½ÃÀå ±Ô¸ð Á¶»ç : ¾à¹° Á¾·ùº°, Åõ¿© °æ·Îº°, À¯Åë ä³Îº°, Áö¿ªº° ¿¹Ãø(2022-2032³â)Global Incretin-Based Drugs Market Size study, by Drug Class, by Route of Administration, by Distribution Channel and Regional Forecasts 2022-2032 |
¼¼°è ÀÎÅ©·¹Æ¾ °ü·Ã ¾à¹° ½ÃÀåÀº 2023³â 371¾ï 4,000¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2024-2032³â ¿¹Ãø ±â°£ µ¿¾È ¿¬Æò±Õ 7.96%ÀÇ °ÇÀüÇÑ ¼ºÀå·ü·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀÎÅ©·¹Æ¾ °ü·Ã ¾à¹°Àº Á¦2Çü ´ç´¢º´ °ü¸®¿¡ »ç¿ëµÇ´Â ¾à¹°ÀÇ ÇÑ Á¾·ùÀÔ´Ï´Ù. ÀÌ ¾à¹°Àº ½Ä»ç¿¡ ¹ÝÀÀÇÏ¿© ÃéÀå¿¡¼ Àν¶¸° ºÐºñ¸¦ ÀÚ±ØÇϴ ȣ¸£¸óÀÎ ÀÎÅ©·¹Æ¾ÀÇ ÀÛ¿ëÀ» ¸ð¹æÇϰųª °ÈÇÕ´Ï´Ù. Àν¶¸° ºÐºñ¸¦ °³¼±ÇÏ°í ±Û·çÄ«°ï ¼öÄ¡¸¦ ³·ÃãÀ¸·Î½á ÀÎÅ©·¹Æ¾ ±â¹Ý Ä¡·áÁ¦´Â Ç÷´ç ¼öÄ¡¸¦ ´õ È¿°úÀûÀ¸·Î Á¶ÀýÇÏ´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ÀϹÝÀûÀÎ ÀÎÅ©·¹Æ¾ °ü·Ã ¾à¹°¿¡´Â GLP-1 ¼ö¿ëü ÀÛ¿ëÁ¦¿Í DPP-4 ¾ïÁ¦Á¦°¡ Æ÷ÇԵǸç, ¸ðµÎ Ç÷´ç Á¶Àý ¹× Àü¹ÝÀûÀÎ ´ç´¢º´ °ü¸® °³¼±¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù.
¼¼°è ÀÎÅ©·¹Æ¾ °ü·Ã ¾à¹° ½ÃÀåÀº Àü ¼¼°è Á¦ 2Çü ´ç´¢º´ À¯º´·ü Áõ°¡¿Í ÀÎÅ©·¹Æ¾ °ü·Ã ¾à¹° ó¹æ Áõ°¡°¡ °áÇÕÇÏ¿© ½ÃÀå ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÀÎÅ©·¹Æ¾ °ü·Ã ¾à¹°Àº Àν¶¸° ºÐºñ¸¦ ÃËÁøÇÏ°í ±Û·çÄ«°ï ¹æÃâÀ» ¾ïÁ¦ÇÏ¿© Ç÷´ç Á¶ÀýÀ» µ½±â ¶§¹®¿¡ Á¦2Çü ´ç´¢º´ °ü¸®¿¡ ÇʼöÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ´ç´¢º´ Ä¡·á¿¡ ´ëÇÑ ÀÌ Çõ½ÅÀûÀÎ Á¢±Ù ¹æ½ÄÀº Àü ¼¼°è ´ç´¢º´ Àα¸ Áõ°¡¿¡ µû¸¥ È¿°úÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇÏ´Â °ÍÀÔ´Ï´Ù. ½ÃÀå È®´ë´Â ÀÎÅ©·¹Æ¾À» ÀÌ¿ëÇÑ ´ç´¢º´ Ä¡·áÁ¦ÀÇ ¿¬±¸°³¹ß¿¡ ´ëÇÑ ¸·´ëÇÑ ÅõÀÚ·Î ÀÎÇØ ´õ¿í °¡¼Óȵǰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °·ÂÇÑ Á¦Ç° ÆÄÀÌÇÁ¶óÀΰú ÁøÇà ÁßÀÎ ¿¬±¸°¡ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª ÀÎÅ© ·¹Æ¾ °ü·Ã ¾à¹°ÀÇ °ú´Ù »ç¿ëÀ¸·Î ÀÎÇÑ ºÎÀÛ¿ë°ú ³ôÀº ºñ¿ëÀ¸·Î ÀÎÇØ ½ÃÀå È®»ê¿¡ °É¸²µ¹ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.
ÀÎÅ©·¹Æ¾ °ü·Ã ¾à¹° ¼¼°è ½ÃÀå Á¶»ç¿¡¼ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, ¶óƾ¾Æ¸Þ¸®Ä« ¹× ±âŸ Áö¿ªÀ¸·Î, 2023³â ¾Æ½Ã¾ÆÅÂÆò¾çÀº ÀÇ·á ÁöÃâ Áõ°¡¿Í ÀÇ·á ÀÎÇÁ¶ó °³¼±À¸·Î ÀÎÇØ ÀÎÅ©·¹Æ¾ °ü·Ã ¾à¹° ½ÃÀå¿¡¼ °¡Àå ºü¸¥ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÎÅ©·¹Æ¾ °ü·Ã ¾à¹° ½ÃÀå¿¡¼ °¡Àå ºü¸£°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Áö¿ªÀº ´ç´¢º´À» Æ÷ÇÔÇÑ ¸¸¼º ÁúȯÀÇ ºÎ´ãÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Çõ½ÅÀûÀ̰í È¿°úÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ¸é¼ ÀÎÅ©·¹Æ¾ °ü·Ã ¾à¹° ½ÃÀåÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ºÏ¹Ì ½ÃÀåÀº 2024-2032³â ¿¹Ãø ±â°£ µ¿¾È ¼öÀÍ Ãø¸é¿¡¼ ¿ìÀ§¸¦ Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
Global Incretin-Based Drugs Market was valued at USD 37.14 billion in 2023, and is anticipated to grow with a healthy growth rate of CAGR of 7.96% during the forecast period 2024-2032. Incretin-based drugs are a class of medications used to manage type 2 diabetes. These drugs mimic or enhance the effects of incretins, which are hormones that stimulate insulin release from the pancreas in response to meals. Through improving insulin secretion and reducing glucagon levels, incretin-based therapies help regulate blood sugar levels more effectively. Common types of incretin-based drugs include GLP-1 receptor agonists and DPP-4 inhibitors, both of which play a significant role in improving glycemic control and overall diabetes management.
The Global Incretin-Based Drugs Market is driven by rise in the prevalence of type 2 diabetes worldwide, coupled with an increase in the prescription of incretin-based drugs for its treatment, is driving the growth of the market. Incretin-based drugs have become essential in managing type 2 diabetes as they help regulate blood glucose levels by boosting insulin secretion and reducing glucagon release. This innovative approach to diabetes therapy addresses the escalating need for effective treatments in the face of a growing global diabetes population. The market's expansion is further fueled by significant investments in research and development of diabetes therapies that utilize incretin. Moreover, a strong pipeline of products and ongoing research are expected to drive the market forward over the forecast period. However, the market faces challenges such as side effects associated with excessive use and the high cost of incretin drugs, which may hinder widespread adoption.
The key regions considered for the Global Incretin-Based Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, Asia-Pacific is poised to be the fastest-growing market for incretin-based drugs owing to rising healthcare expenditure and improving healthcare infrastructure. The increasing burden of chronic diseases including diabetes in this region underscores the demand for innovative and effective treatments, thereby expanding the market for incretin-based drugs. Furthermore, the market in North America is anticipated to dominate in terms of revenue over the forecast period 2024-2032.